Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Defunding Co-Payment Assistance Disrupted nAMD Care
4
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
5